The purpose of this study is to evaluate the investigational use of 2 drugs, pembrolizumab and olaparib, on patients with advanced BRCA-mutated or HDR-defect breast cancer that has progressed (worsened) after previous treatment. BRCA1 and BRCA2 are genes that play a role in protecting cells from cancer. If one of these genes is mutated, cells may rapidly change and divide, which can lead to cancer. HDR-defect is another type of gene mutation that can contribute to development and progression of cancer. Pembrolizumab and olaparib work with the immune system to target tumors. Researchers aim to determine whether pembrolizumab and olaparib together will be able to reduce the size and amount of cancer cells with fewer side effects than standard treatment by targeting the participant’s tumor.
What is the full name of this clinical trial?
IIT2015-18-MITA-MK3475: Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
Alain Mita, Dorothy Park, Jin Sun Bitar, Maryliza El-Masry, Philomena McAndrew, Yuan Yuan